Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Tumor Progression02:07

Tumor Progression

7.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

6.6K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.5K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

10.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy.

Frontiers in oncology·2024
Same author

Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer.

Molecular cancer therapeutics·2024
Same author

SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression.

Cancer research communications·2023
Same author

[Surgical treatment of 402 consecutive cases for hilar cholangiocarcinoma: Chinese single center experience].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2007
Same author

Highly convergent route to cyclopeptide alkaloids: total synthesis of ziziphine N.

Organic letters·2007
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Dec 8, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.3K

EVI1 in Leukemia and Solid Tumors.

Beiyuan Liang1, Jing Wang1

  • 1Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.

Cancers
|September 23, 2020
PubMed
Summary
This summary is machine-generated.

The EVI1 gene and its related proteins play roles in various cancers. This review summarizes their structures, properties, and functions in cancer development, highlighting EVI1

Keywords:
AML1/MDS1/EVI1EVI1MDS1/EVI1cancerleukemiasolid tumorstranscription factors

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

568
Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
10:09

Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment

Published on: June 2, 2020

7.2K

Related Experiment Videos

Last Updated: Dec 8, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.3K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

568
Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
10:09

Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment

Published on: June 2, 2020

7.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • The EVI1 gene encodes a transcription factor implicated in myeloid leukemias and solid tumors.
  • EVI1 activation in leukemia often results from chromosomal rearrangements.
  • EVI1 functions as a transcriptional repressor, while MDS1/EVI1 acts as an activator.

Purpose of the Study:

  • To review the genetic structures, biochemical properties, and biological functions of EVI1, MDS1/EVI1, and AML1/MDS1/EVI1 proteins in cancer.
  • To consolidate current knowledge on the roles of these proteins in various malignancies.
  • To identify knowledge gaps regarding the functions of MDS1/EVI1 and AML1/MDS1/EVI1.

Main Methods:

  • Literature review of studies on EVI1, MDS1/EVI1, and AML1/MDS1/EVI1.
  • Analysis of genetic structures and biochemical properties.
  • Summary of reported biological functions in cancer contexts.

Main Results:

  • EVI1 is transcriptionally activated in myeloid leukemias and linked to breast, lung, ovarian, and colon cancers.
  • The AML1/MDS1/EVI1 fusion protein, found in chronic myeloid leukemia, shares functional similarities with EVI1.
  • EVI1 regulates cell proliferation, differentiation, and apoptosis, but functions of MDS1/EVI1 and AML1/MDS1/EVI1 are less understood.

Conclusions:

  • EVI1 and its related proteins are significant in cancer pathogenesis.
  • Further research is needed to elucidate the precise functions of MDS1/EVI1 and AML1/MDS1/EVI1 in cancer.
  • Understanding these proteins' roles can inform cancer diagnostics and therapeutics.